One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Adicet Bio logo
Adicet Bio ACET
$ 3.0 1.69%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Adicet Bio Income Statement 2025-2011 | ACET

Brief overview of financial performance at Adicet Bio

The overview follows changes across a five-year period. Revenue at Adicet Bio moved from 559 million dollars in 2017 to 25 million dollars in 2022. The total change was −95.5%, with a CAGR of approximately −46.3%. Revenue ended the period on a sustained downward trend.

The five-year EBITDA result moved by −194.3%: from $74.2 million to −$70 million. EBITDA underperformed the top-line trend. EBITDA margin was 13.3% at the start and −280% at the end. A lower EBITDA share weakens the quality of the result.

Across the five years, the net result shifted from 34.8 million dollars to −69.8 million dollars. Profit turned into a loss, the most concerning signal in the results.

Summary assessment

The financial trajectory is weak and requires a cautious interpretation. The overall view is constrained by a weaker final result, limited operating profitability and a softer top-line trend. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Adicet Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

48.5 M 4.61 M 87.4 M 317 M 541 M 64.1 M 289 M - - - - - - - -

Shares

6.89 M 5.49 M 43 M 41.1 M 31 M 5.21 M 32.3 M - - - - - - - -

Historical Prices

7.04 0.84 2.03 7.72 17.5 14.1 10.4 60.3 - - - - - - -

Net Income

-117 M -117 M -143 M -69.8 M -62 M -36.7 M -28.1 M 11.4 M 34.8 M 33.5 M 29 M 22.3 M 22.3 M 17 M 8.97 M

Revenue

- - - 25 M 9.73 M 17.9 M 995 K 638 M 559 M 547 M 510 M 500 M 500 M 444 M 412 M

Gross Profit

- - - - - 17.9 - 141 M 143 M 135 M 115 M 98.3 M 98.3 M 82 M 65.8 M

Operating Income

-122 M -128 M -152 M -72.6 M -61.4 M -39.2 M -31.4 M -15 M -18.9 M - - - - - -

Interest Expense

36 K 4 K 25 K 80 K 176 K 134 K 2.33 M 4.53 M -14.9 M - - - - - -

EBITDA

-116 M -121 M -146 M -70 M -59.9 M -38 M -30.2 M 65.2 M 74.2 M 68.2 M 52.4 M 41.4 M 41.4 M 32.3 M 22.1 M

Operating Expenses

122 M 128 M 152 M 97.5 M 71.2 M 57.1 M - 110 M 84.8 M 79.1 M 70.4 M 63.9 M 63.9 M 56.7 M 49.3 M

General and Administrative Expenses

23 M 28.3 M 26.5 M 26.3 M 22.2 M 22.8 M 8.69 M 102 M 76.8 M 73.2 M 65.2 M 61 M 63.9 M 56.7 M 49.3 M

All numbers in USD currency

Quarterly Income Statement Adicet Bio

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

10.7 M 10.7 M 10.7 M 1.18 M 5.69 M 5.69 M 5.69 M -81.4 M 90.8 M 90.6 M 79.1 M 40.5 M 43 M 43 M 43 M 532 K 41.6 M 40.1 M 39.8 M 998 K 31.9 M 31.8 M 26.1 M 4.13 M 5.21 M 2.18 M 2.16 M 5.33 K 2.15 M 35.7 M 29 M 28.1 M 28 M 28 M 21.5 M 5.66 M 4.41 M 4.3 M 2.79 M - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-18.9 M -21.4 M -20.2 M -30.5 M -26.9 M -31.2 M -28.2 M -28.7 M -30.5 M -29.9 M -28 M -29.5 M -49.9 M -32.4 M -30.9 M -29.9 M -22 M -22.5 M 4.62 M -15.8 M -14 M -10.9 M -21.3 M -8.96 M -14.8 M -8.46 M -4.49 M -28.9 M -14.8 M -2.65 M -11.1 M -5.76 M -8.41 M -13.6 M -9.86 M -23.1 M -3.31 M -4.06 M -3.36 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - - - - - - 25 M 5.47 M 3.43 M 4.81 M -3.98 M 5.41 M 3.03 M 7.46 M 2 M 1.97 M -7.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-19.8 M -22.3 M -21.6 M -31.9 M -28 M -32.4 M -29.9 M -30.7 M -33.2 M -32.8 M -30.9 M -31.6 M -52.3 M -34.9 M -33.3 M -31.6 M -23 M -22.7 M 4.71 M -15.5 M -13.7 M -10.8 M -21.4 M -9.35 M -13.7 M -8.63 M -7.56 M -29.4 M -15.2 M -19.2 M -11.7 M -6.36 M -9.03 M -14.1 M -10.2 M -7.52 M -3.94 M -4.06 M -3.36 M - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-30 K -60 K 7 K -130 K -64 K -223 K -12 K -50 K -54 K -51 K -61 K -101 K -142 K -124 K -206 K -463 K -217 K -138 K -102 K -294 K -246 K -62 K -4 K 221 K -1.22 M -20 K 70 K 240 K 171 K 847 K 631 K - 625 K 522 K 341 K - 635 K - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-18.8 M -21.1 M -20.2 M -30.4 M -26.4 M -30.7 M -28.2 M -29.1 M -31.6 M -31.2 M -29.2 M -29.8 M -50.7 M -33.4 M -32.1 M -30.5 M -22.2 M -22.3 M 5.06 M -15.2 M -13.3 M -10.3 M -21 M -9.03 M -13.4 M -8.33 M -7.24 M -29.7 M -14.9 M -19.1 M -11.7 M -6.36 M -9.01 M -14.1 M -10.2 M -7.52 M -3.94 M -4.06 M -3.36 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

19.8 M 22.3 M 21.6 M 31.9 M 28 M 32.4 M 29.9 M 30.7 M 33.2 M 32.8 M 30.9 M 31.6 M 52.3 M 34.9 M 33.3 M 31.6 M 23 M 22.7 M 20.3 M 21 M 17.1 M 15.6 M 17.4 M 14.8 M 16.7 M 16.1 M 9.56 M 9.15 M 8.18 M 19.2 M 11.7 M 6.36 M 9.03 M 14.1 M 10.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.17 M 3.85 M 4.08 M 6.85 M 5.1 M 3.97 M 7.07 M 7.47 M 6.9 M 6.95 M 6.97 M 6.81 M 6.63 M 6.53 M 6.57 M 6.55 M 6.42 M 6.53 M 6.8 M 6.35 M 5.21 M 5.02 M 5.63 M 5.08 M 7.74 M 7.42 M 2.52 M 2.62 M 1.85 M 2.62 M 2.84 M - 2.27 M 2.27 M 2.09 M - 612 K 637 K 63 K - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Adicet Bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Chemicals industry

Issuer Price % 24h Market Cap Country
Казаньоргсинтез Казаньоргсинтез
KZOS
- - - russiaRussia
LSB Industries LSB Industries
LXU
$ 10.52 1.74 % $ 756 M usaUSA
Methanex Corporation Methanex Corporation
MEOH
$ 66.39 1.42 % $ 4.82 B canadaCanada
Celanese Corporation Celanese Corporation
CE
$ 46.52 -2.78 % $ 5.1 B usaUSA
Куйбышевазот Куйбышевазот
KAZT
- - - russiaRussia
Braskem S.A. Braskem S.A.
BAK
$ 1.09 2.36 % $ 463 M brasilBrasil
Роллман Роллман
RLMN
- - - russiaRussia
Tronox Holdings plc Tronox Holdings plc
TROX
$ 2.48 -4.8 % $ 393 M usaUSA
FutureFuel Corp. FutureFuel Corp.
FF
$ 5.33 -1.48 % $ 234 M usaUSA
Westlake Chemical Partners LP Westlake Chemical Partners LP
WLKP
$ 21.14 -0.94 % $ 745 M usaUSA
Dow Dow
DOW
$ 31.39 -1.81 % $ 22.3 B usaUSA
Univar Solutions Univar Solutions
UNVR
- -0.01 % $ 5.99 B usaUSA
Huntsman Corporation Huntsman Corporation
HUN
$ 9.44 -3.38 % $ 1.63 B usaUSA
Air Products and Chemicals Air Products and Chemicals
APD
$ 305.66 -1.24 % $ 68.1 B usaUSA
DuPont de Nemours DuPont de Nemours
DD
$ 146.56 1.08 % $ 61.2 B usaUSA
AdvanSix AdvanSix
ASIX
$ 16.7 2.96 % $ 449 M usaUSA
Ashland Global Holdings Ashland Global Holdings
ASH
$ 76.36 0.1 % $ 3.51 B usaUSA
Eastman Chemical Company Eastman Chemical Company
EMN
$ 64.37 -2.01 % $ 7.38 B usaUSA
Rayonier Advanced Materials Rayonier Advanced Materials
RYAM
$ 5.96 -8.67 % $ 398 M usaUSA
Sociedad Química y Minera de Chile S.A. Sociedad Química y Minera de Chile S.A.
SQM
$ 57.48 1.97 % $ 16.4 B chileChile
Molecular Data Molecular Data
MKD
- 2.5 % $ 2.3 M chinaChina
Ciner Resources LP Ciner Resources LP
CINR
- 0.81 % $ 344 M usaUSA
Valhi Valhi
VHI
$ 16.69 12.09 % $ 476 M usaUSA
Minerals Technologies Minerals Technologies
MTX
$ 61.55 -1.47 % $ 1.93 B usaUSA
Нижнекамскнефтехим Нижнекамскнефтехим
NKNC
- - - russiaRussia